The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.
Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.
SEE ALSO...
Items 1 to 10 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
NBQX is an AMPA receptor antagonist, which can indirectly affect glutamate signaling and release. | ||||||
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $97.00 | 2 | |
As an NMDA receptor antagonist, AP5 can indirectly influence glutamate signaling and release. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX is a potent AMPA receptor antagonist, indirectly affecting glutamate signaling and release. | ||||||
Kynurenic acid | 492-27-3 | sc-202683 sc-202683A sc-202683B | 250 mg 1 g 5 g | $26.00 $57.00 $138.00 | 6 | |
This is a broad-spectrum antagonist for excitatory amino acid receptors, thus reducing glutamate signaling. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $193.00 $213.00 $317.00 | 1 | |
Riluzole inhibits the release of glutamate, influencing the function of SLC17A7 indirectly. | ||||||
Memantine hydrochloride | 41100-52-1 | sc-203628 | 50 mg | $69.00 | 4 | |
This is an NMDA receptor antagonist, indirectly affecting glutamate signaling. | ||||||
Ethosuximide | 77-67-8 | sc-211431 | 1 g | $306.00 | ||
This compound reduces T-type calcium channel activity, which can indirectly influence glutamate release. | ||||||
Lamotrigine | 84057-84-1 | sc-201079 sc-201079A | 10 mg 50 mg | $120.00 $486.00 | 1 | |
Lamotrigine inhibits voltage-sensitive sodium channels, leading to a decrease in glutamate release. | ||||||
Topiramate | 97240-79-4 | sc-204350 sc-204350A | 10 mg 50 mg | $107.00 $369.00 | ||
It modulates GABA-evoked currents, indirectly influencing glutamate release. | ||||||
Felbamate | 25451-15-4 | sc-203579 sc-203579A | 10 mg 50 mg | $101.00 $373.00 | ||
Felbamate acts as a NMDA receptor antagonist, indirectly affecting glutamate signaling and release. | ||||||